#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Endometrial cancer Chronic graft versus host disease in skin Familial dilated cardiomyopathy Adrenoleukodystrophy Synovial sarcoma recurrent Primary myelofibrosis Pustular psoriasis Mantle cell lymphoma stage II Sarcoma Ornithine transcarbamoylase deficiency Peripheral primitive neuroectodermal tumour of soft tissue High-grade B-cell lymphoma Krabbe's disease Retinal artery occlusion Hereditary spastic paraplegia More trials…

    Learn about Rare Diseases

    Stevens-Johnson syndrome – Basic Information Chondrosarcoma metastatic Toxic epidermal necrolysis – Treatment Sarcoidosis – Diagnostics Mitochondrial myopathy – Basic Information Pulmonary sarcoidosis – Treatment Methylmalonic acidaemia – Basic Information Richter’s syndrome – Treatment Malignant fibrous histiocytoma Synovial sarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Valiltramiprosate Pyrimethamine Mbs2320 Leriglitazone RNMB1 Human Serum Albumin 5% Tofacitinib Citrate Davutamig VANADIUM OXIDE SULFATE Int-787 Indacaterol Maleate Egl-001 Lt3001 Intestifix Prasterone Lisaftoclax Lenzumestrocel Sacituzumab Tirumotecan Sodium Chloride Ezetimibe More therapies…

    Learn about Your Condition

    Anaemia of pregnancy BRAF gene mutation Chondroplasty Choroidal dystrophy Optic atrophy Myofascial pain syndrome Ewing's sarcoma Post-traumatic headache IgA nephropathy Spinal muscular atrophy Stomatitis Intestinal ischaemia Takayasu's arteritis Knee arthroplasty Crigler-Najjar syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HER2 positive breast cancer

  • Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    • Pertuzumab
    France

  • Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer female
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Germany

  • A study of Zr89-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Emtansine
    • Trastuzumab
    Belgium

  • Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Disitamab Vedotin
    • Tucatinib
    France Germany Italy Spain

  • Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Trastuzumab Emtansine
    • Trastuzumab
    Belgium The Netherlands

  • Study of BB-1701 for Patients with HER2-positive or HER2-low Metastatic Breast Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • HER2 positive breast cancer
    Investigated Drugs:
    • Humanised Igg1 Kappa Monoclonal Antibody Against Receptor Tyrosine-Protein Kinase Erbb-2 Conjugated To Eribulin
    France Germany Spain
Previous Page
1 2 3 4 5 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!